Qilian International Holding Group Limited Announces Inclusion of 16 Products into China's National Reimbursement Drugs List
April 13 2021 - 7:00AM
Qilian International Holding Group Limited (Nasdaq: QLI) (the
“Company”), a China-based pharmaceutical and chemical products
manufacturer, today announced that 16 of its products have been
included in the latest version of the National Reimbursement Drugs
List in China, such as aspirin enteric-coated tablets for coronary
heart disease treatment, and nitrofurantoin enteric-coated tablets
for the treatment of urinary tract infections. In addition, 10 out
of these 16 products have been included in the latest version of
the National Essential Medicines List in China.
National Reimbursement Drug List is the list of
products eligible for reimbursement in China, as maintained by the
National Healthcare Commission of China. The National Essential
Medicines List is one of the core contents of the essential
medicines system. The system requires that all government-run
primary health care institutions be equipped with essential
medicines merely and on the respective lists of each province.
China’s National Healthcare Security
Administration has added 119 products to the National Reimbursement
Drugs List effective from March 2021. The list also includes some
key products produced by foreign pharmaceutical companies, such as
Novartis’ blockbuster inflammation drug Cosentyx, and Israeli firm
Teva Pharmaceuticals’ Austedo for treatment of involuntary
movements of Huntington’s disease in adults. Inclusion into the
list could potentially boost demand for these drugs, as patients
will be reimbursed for a significant portion of the costs of
purchasing these listed drugs.
Mr. Zhanchang Xin, Chairman and CEO of the
Company, commented, “We are excited to have 16 of our products
included in the National Reimbursement Drugs List and 10 out of
these 16 products also included in the National Essential Medicines
List in China. This means that our products may benefit from being
included on such list and their market share grow
consequently.”
About Qilian International Holding Group
Limited
Qilian International Holding Group Limited,
headquartered in Gansu, China, is a pharmaceutical and chemical
products manufacturer in China. It focuses on the development,
manufacture, marketing and sale of licorice products,
oxytetracycline products, traditional Chinese medicine derivatives
product, heparin product, sausage casings, and fertilizers. The
Company’s products are sold in more than 20 provinces in China. For
more information, visit the company’s website at
http://ir.qlsyy.net/.
Forward-Looking Statements
This announcement contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements
other than statements of historical fact in this announcement are
forward-looking statements. These forward-looking statements
involve known and unknown risks and uncertainties and are based on
current expectations and projections about future events and
financial trends that the Company believes may affect its financial
condition, results of operations, business strategy and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company undertakes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company’s registration statement and in its other filings with the
SEC.
For more information, please
contact:
Qilian International Holding Group
Limited Email: ir@qlsyy.net
Ascent Investors Relations
LLCTina Xiao PresidentPhone:
917-609-0333Email: tina.xiao@ascent-ir.com
Qilian (NASDAQ:QLI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Qilian (NASDAQ:QLI)
Historical Stock Chart
From Sep 2023 to Sep 2024